Detail akcie Nutriband Rg online

Business Summary: Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Financial Summary: BRIEF: For the nine months ended 31 October 2025, Nutriband Inc revenues increased 9% to $1.6M. Net loss applicable to common stockholders increased from $5M to $29.1M. Revenues reflect Non-United States segment increase from $0K to $8K. Higher net loss reflects Selling, general and administrative expe increase from $2.6M to $6.1M (expense), Interest Income decrease of 64% to $53K (income).